Therefore, we focused on the anti-oncogenic effects of 5α-reductase inhibition and evaluated the effects on cancer progression of the dutasteride target genes SRD5A1 and SRD5A2, encoding 5α-reductase Type 1 and 2, respectively. The gene discussed is SRD5A1; the disease is cancer.